References
- JFC. British National Formulary. 70 ed. London: BMJ Group and Pharmaceutical Press; 2015.
- Food and Drug Administration. BLA 125544: CT-P13, a proposed biosimilar to Remicade (Infliximab). 2016 Feb 09. [cited 2016 May 05]. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM484859.pdf
- Klotz U, Teml A, Schwab M. Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet. 2007;46(8):645–660.
- European Medicines Agency. Questions and answers on biosimilar medicines (similar biological medicinal products). 2012. [cited 2016 Feb 23]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2009/12/WC500020062.pdf
- Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013;72(10):1613–1620.
- European Medicines Agency. Assessment Report: Remsima. 2013. Available from http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002576/WC500151486.pdf
- Yoo DH, Oh C, Hong S, et al. Analysis of clinical trials of biosimilar infliximab (CT-P13) and comparison against historical clinical studies with the infliximab reference medicinal product. Expert Rev Clin Immunol. 2015;11(Suppl 1):S15–S24.
- Yoo DH, Prodanovic N, Jaworski J, et al. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. Ann Rheum Dis. 2016 Apr 29. doi:10.1136/annrheumdis-2015-208786. [Epub ahead of print]
- Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013;72(10):1605–1612.
- Lee Y, Shin D, Yea K. A phase I pharmacokinetic study comparing SB4, an etanercept biosimilar, and etanercept reference product (Enbrel®) in healthy male subjects. Ann Rheum Dis. 2015;74(Suppl.2):718. doi:10.1136/annrheumdis-2015-eular.2671
- Emery P, Vencovsky J, Sylwestrzak A, et al. A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2015 Jul 6. doi:10.1136/annrheumdis-2015-207588. [Epub ahead of print].
- Marshall L, Hickling T, Bill D, et al. Comparing the immunogenicity of the etanercept biosimilar SB4 with the innovator etanercept: another consideration. Ann Rheum Dis. 2016 Mar 31. doi:10.1136/annrheumdis-2016-209502. [Epub ahead of print].
- Emery P, Vencovský J, Ghil J, et al. Response to: ‘Comparing the immunogenicity of the etanercept biosimilar SB4 with the innovator etanercept: another consideration’ by Marshall et al. Ann Rheum Dis. 2016 May 4. doi:10.1136/annrheumdis-2016-209517. [Epub ahead of print].
- British Society of Rheumatology. Position Statement on Biosimilar Products. 2015 Feb. Available from: http://www.rheumatology.org.uk/includes/documents/cm_docs/2015/b/bsr_biosimilars_position_statement_feb_2015.pdf